Tempus AI, Inc. (NASDAQ:TEM) is highlighted as one of the best digital health stocks to buy now. Following a strong Q3, Wall Street sentiment towards Tempus AI improved, with three major firms reiterating positive ratings. Canaccord Genuity maintained a Buy rating but adjusted its target slightly to $95, noting the potential for AI deployment at scale in clinical practice to drive revenue growth.

Tempus AI, Inc. utilizes artificial intelligence to personalize treatment based on clinical and molecular data, particularly in oncology. The company’s blowout Q3 performance was attributed to the Ambry-boosted genomics engine, leading to increased genomics revenue and overall sales growth. Insights licensing and cost management strategies contributed to positive adjusted EBITDA.

While acknowledging the investment potential of TEM, some believe there are AI stocks with greater upside potential and lower downside risk. For those seeking undervalued AI stocks with potential benefits from Trump-era tariffs and the onshoring trend, a free report on the best short-term AI stock is recommended. The market’s focus on costs and future spending led to a temporary market wobble for Tempus AI despite strong demand and growth levers.

Read more at Yahoo Finance: Tempus AI Retains Buy Rating as Canaccord Adjusts Price Target to $95 After Q3 Beat